<p><strong>安斯泰莱制药 (ADR)</strong> (TSE:4503) 的股东们可能感到有些失望，因为在其最新年度业绩发布后的一个星期内，股价下跌了 7.8%，降至 JP¥2,306。JP¥2.1 万亿的收入与预期一致，尽管法定每股收益（EPS）为 JP¥163，低于预期，差距为 4.8%。对于投资者来说，这是一个重要的时刻，因为他们可以在报告中跟踪公司的表现，查看专家对明年的预测，并观察业务预期是否有所变化。因此，我们收集了最新的财报后预测，以了解估计值对明年的展望。</p>
<p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</p>
<p>考虑到最新的业绩，安斯泰莱制药的十二位分析师的共识预测是 2027 年的收入为 JP¥2.24 万亿。这反映出与过去 12 个月相比，收入有温和的 4.5% 的改善。每股收益预计将增长 13%，达到 JP¥184。在这份报告发布之前，分析师们曾预测 2027 年的收入为 JP¥2.22 万亿，每股收益（EPS）为 JP¥192。因此，近期业绩后，整体情绪似乎略有下降——收入预期没有重大变化，但分析师们对每股收益的预测进行了小幅下调。</p>
<p>查看我们对安斯泰莱制药的最新分析</p>
<p>可能令人惊讶的是，分析师们的共识目标价基本保持不变，为 JP¥2,418，显然暗示预期的收益下降不会对估值产生太大影响。不过，还有另一种看待目标价的方法，那就是查看分析师提出的目标价范围，因为广泛的估计范围可能表明对业务可能结果的多样化看法。对安斯泰莱制药的看法存在一些差异，最乐观的分析师将其估值为 JP¥2,950，而最悲观的则为每股 JP¥1,600。正如你所看到的，分析师们对该股票的未来并不完全一致，但估计范围仍然相对狭窄，这可能表明结果并非完全不可预测。</p>
<p>这些估计很有趣，但在比较预测时，考虑安斯泰莱制药的过去表现以及同行业的公司时，描绘一些更广泛的趋势是有用的。我们要强调的是，安斯泰莱制药的收入增长预计将放缓，预计到 2027 年底的年化增长率为 4.5%，远低于过去五年 11% 的历史年增长率。与该行业中 41 家有分析师覆盖的公司相比，预计它们的收入年增长率为 4.1%。考虑到增长放缓的预测，安斯泰莱制药的增长率预计与更广泛的行业大致相同。</p>
<h2>结论</h2>
<p>最重要的是，分析师们下调了他们的每股收益预测，显示出在这些业绩发布后情绪明显下降。他们还重新确认了收入预测，预计公司将以与更广泛行业相似的速度增长。共识目标价没有实质性变化，表明最新的估计并未对业务的内在价值产生重大影响。</p>
<p>考虑到这一点，我们不应过快得出关于安斯泰莱制药的结论。长期的盈利能力远比明年的利润更为重要。在 Simply Wall St，我们有安斯泰莱制药到 2029 年的完整分析师估计，你可以在我们的平台上免费查看。</p>
<p>不过，你应该始终考虑风险。举个例子，我们发现了 <strong>1 个安斯泰莱制药的警示信号</strong>，你应该注意。</p>

安斯泰莱制药(ADR)

4503

<p>安斯泰莱制药 (ADR)（东京证券交易所代码：4503）公布了年度财报，股价下跌 7.8%，至 2,306 日元。收入达到预期，为 2.1 万亿日元，但每股收益（EPS）未达标，为 163 日元，低于预期 4.8%。分析师预测 2027 年的收入为 2.24 万亿日元，反映出 4.5% 的增长，而每股收益预计将增长 13%，达到 184 日元。尽管每股收益的预期被下调，但共识目标价仍保持在 2,418 日元。安斯泰莱制药的增长预计将与行业趋势保持一致，但分析师对该股票的未来看法各异</p>

<p><strong>Astellas Pharma Inc.</strong> (TSE:4503) shareholders are probably feeling a little disappointed, since its shares fell 7.8% to JP¥2,306 in the week after its latest yearly results. Revenues of JP¥2.1t were in line with forecasts, although statutory earnings per share (EPS) came in below expectations at JP¥163, missing estimates by 4.8%. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.</p>
<div class="lb-trans"><p><strong>安斯泰莱制药 (ADR)</strong> (TSE:4503) 的股东们可能感到有些失望，因为在其最新年度业绩发布后的一个星期内，股价下跌了 7.8%，降至 JP¥2,306。JP¥2.1 万亿的收入与预期一致，尽管法定每股收益（EPS）为 JP¥163，低于预期，差距为 4.8%。对于投资者来说，这是一个重要的时刻，因为他们可以在报告中跟踪公司的表现，查看专家对明年的预测，并观察业务预期是否有所变化。因此，我们收集了最新的财报后预测，以了解估计值对明年的展望。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</p>
</div><p>Taking into account the latest results, the consensus forecast from Astellas Pharma's twelve analysts is for revenues of JP¥2.24t in 2027. This reflects a modest 4.5% improvement in revenue compared to the last 12 months. Per-share earnings are expected to expand 13% to JP¥184. In the lead-up to this report, the analysts had been modelling revenues of JP¥2.22t and earnings per share (EPS) of JP¥192 in 2027. So it looks like there's been a small decline in overall sentiment after the recent results - there's been no major change to revenue estimates, but the analysts did make a minor downgrade to their earnings per share forecasts.</p>
<div class="lb-trans"><p>考虑到最新的业绩，安斯泰莱制药的十二位分析师的共识预测是 2027 年的收入为 JP¥2.24 万亿。这反映出与过去 12 个月相比，收入有温和的 4.5% 的改善。每股收益预计将增长 13%，达到 JP¥184。在这份报告发布之前，分析师们曾预测 2027 年的收入为 JP¥2.22 万亿，每股收益（EPS）为 JP¥192。因此，近期业绩后，整体情绪似乎略有下降——收入预期没有重大变化，但分析师们对每股收益的预测进行了小幅下调。</p>
</div><p>View our latest analysis for Astellas Pharma</p>
<div class="lb-trans"><p>查看我们对安斯泰莱制药的最新分析</p>
</div><p>It might be a surprise to learn that the consensus price target was broadly unchanged at JP¥2,418, with the analysts clearly implying that the forecast decline in earnings is not expected to have much of an impact on valuation. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Astellas Pharma, with the most bullish analyst valuing it at JP¥2,950 and the most bearish at JP¥1,600 per share. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.</p>
<div class="lb-trans"><p>可能令人惊讶的是，分析师们的共识目标价基本保持不变，为 JP¥2,418，显然暗示预期的收益下降不会对估值产生太大影响。不过，还有另一种看待目标价的方法，那就是查看分析师提出的目标价范围，因为广泛的估计范围可能表明对业务可能结果的多样化看法。对安斯泰莱制药的看法存在一些差异，最乐观的分析师将其估值为 JP¥2,950，而最悲观的则为每股 JP¥1,600。正如你所看到的，分析师们对该股票的未来并不完全一致，但估计范围仍然相对狭窄，这可能表明结果并非完全不可预测。</p>
</div><p>These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Astellas Pharma's past performance and to peers in the same industry. We would highlight that Astellas Pharma's revenue growth is expected to slow, with the forecast 4.5% annualised growth rate until the end of 2027 being well below the historical 11% p.a. growth over the last five years. Compare this to the 41 other companies in this industry with analyst coverage, which are forecast to grow their revenue at 4.1% per year. Factoring in the forecast slowdown in growth, it looks like Astellas Pharma is forecast to grow at about the same rate as the wider industry.</p>
<div class="lb-trans"><p>这些估计很有趣，但在比较预测时，考虑安斯泰莱制药的过去表现以及同行业的公司时，描绘一些更广泛的趋势是有用的。我们要强调的是，安斯泰莱制药的收入增长预计将放缓，预计到 2027 年底的年化增长率为 4.5%，远低于过去五年 11% 的历史年增长率。与该行业中 41 家有分析师覆盖的公司相比，预计它们的收入年增长率为 4.1%。考虑到增长放缓的预测，安斯泰莱制药的增长率预计与更广泛的行业大致相同。</p>
</div><h2>The Bottom Line</h2>
<div class="lb-trans"><h2>结论</h2>
</div><p>The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.</p>
<div class="lb-trans"><p>最重要的是，分析师们下调了他们的每股收益预测，显示出在这些业绩发布后情绪明显下降。他们还重新确认了收入预测，预计公司将以与更广泛行业相似的速度增长。共识目标价没有实质性变化，表明最新的估计并未对业务的内在价值产生重大影响。</p>
</div><p>With that in mind, we wouldn't be too quick to come to a conclusion on Astellas Pharma. Long-term earnings power is much more important than next year's profits. At Simply Wall St, we have a full range of analyst estimates for Astellas Pharma going out to 2029, and you can see them free on our platform here..</p>
<div class="lb-trans"><p>考虑到这一点，我们不应过快得出关于安斯泰莱制药的结论。长期的盈利能力远比明年的利润更为重要。在 Simply Wall St，我们有安斯泰莱制药到 2029 年的完整分析师估计，你可以在我们的平台上免费查看。</p>
</div><p>You should always think about risks though. Case in point, we've spotted <strong>1 warning sign for Astellas Pharma</strong> you should be aware of.</p>
<div class="lb-trans"><p>不过，你应该始终考虑风险。举个例子，我们发现了 <strong>1 个安斯泰莱制药的警示信号</strong>，你应该注意。</p>
</div>

安斯泰莱制药 (ADR)（TSE:4503）刚刚公布了年度财报：分析师对该股票的看法是否有所改变？